Cargando…

Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling

Constitutive JAK/STAT3 signaling contributes to disease progression in many lymphoproliferative disorders. Recent genetic analyses have revealed gain-of-function STAT3 mutations in lymphoid cancers leading to hyperactivation of STAT3, which may represent a potential therapeutic target. Using a funct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuusanmäki, Heikki, Dufva, Olli, Parri, Elina, van Adrichem, Arjan J., Rajala, Hanna, Majumder, Muntasir M., Yadav, Bhagwan, Parsons, Alun, Chan, Wing C., Wennerberg, Krister, Mustjoki, Satu, Heckman, Caroline A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722580/ https://www.ncbi.nlm.nih.gov/pubmed/29228628 http://dx.doi.org/10.18632/oncotarget.22178

Ejemplares similares

Identification of novel regulators of STAT3 activity
por: Parri, Elina, et al.
Publicado: (2020)

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
por: Malani, Disha, et al.
Publicado: (2022)

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2020)

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types
por: Majumder, Muntasir M., et al.
Publicado: (2020)

Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing
por: Majumder, Muntasir Mamun, et al.
Publicado: (2017)

Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia
por: Hohtari, Helena, et al.
Publicado: (2022)

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
por: Yadav, Bhagwan, et al.
Publicado: (2014)

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
por: Dufva, Olli, et al.
Publicado: (2018)

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors
por: Pietarinen, Paavo O., et al.
Publicado: (2017)

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2022)

JAK-STAT in lymphoproliferative disorders
por: Rabadan, Raul, et al.
Publicado: (2015)

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2023)

STAT5b in LGL leukemia – a novel therapeutic target?
por: Rajala, Hanna L. M., et al.
Publicado: (2013)

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
por: Pietarinen, P O, et al.
Publicado: (2015)

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
por: Eldfors, S, et al.
Publicado: (2017)

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
por: Yadav, Bhagwan, et al.
Publicado: (2015)

Corrigendum to “Searching for drug synergy in complex dose–response landscapes using an interaction potency model” [Comput. Struct. Biotechnol. J. 13 (2015) 504–513]
por: Yadav, Bhagwan, et al.
Publicado: (2017)

Discovery of MINC1, a GTPase-Activating Protein Small Molecule Inhibitor, Targeting MgcRacGAP
por: van Adrichem, Arjan J., et al.
Publicado: (2015)

Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors
por: Cichonska, Anna, et al.
Publicado: (2017)

The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
por: TÜRK, Can, et al.
Publicado: (2019)

Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia
por: White, Brian S., et al.
Publicado: (2021)

P409: BCL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA
por: Vänttinen, Ida, et al.
Publicado: (2023)

The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients
por: Schubert, Claudia, et al.
Publicado: (2017)

RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
por: Adnan Awad, Shady, et al.
Publicado: (2020)

Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
por: Ianevski, Aleksandr, et al.
Publicado: (2021)

A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells
por: Gasparini, Vanessa Rebecca, et al.
Publicado: (2020)

Target Inhibition Networks: Predicting Selective Combinations of Druggable Targets to Block Cancer Survival Pathways
por: Tang, Jing, et al.
Publicado: (2013)

Mutations in JAK/STAT and NOTCH1 Genes Are Enriched in Post-Transplant Lymphoproliferative Disorders
por: Butzmann, Alexandra, et al.
Publicado: (2022)

The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia
por: Kumar, Ashwini, et al.
Publicado: (2017)

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells
por: Gautam, Prson, et al.
Publicado: (2016)

Standardized assays to monitor drug sensitivity in hematologic cancers
por: Ayuda-Durán, Pilar, et al.
Publicado: (2023)

Breeze: an integrated quality control and data analysis application for high-throughput drug screening
por: Potdar, Swapnil, et al.
Publicado: (2020)

JAK‐STAT core cancer pathway: An integrative cancer interactome analysis
por: Erdogan, Fettah, et al.
Publicado: (2022)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

From drug response profiling to target addiction scoring in cancer cell models
por: Yadav, Bhagwan, et al.
Publicado: (2015)

A novel class of somatic mutations in blood detected preferentially in CD8 + cells
por: Valori, Miko, et al.
Publicado: (2017)

P1228: GENOME-WIDE CRISPR-CAS9 SCREENING IDENTIFIES THERAPEUTIC TARGETS FOR MATURE T-CELL MALIGNANCIES
por: Timonen, Sanna, et al.
Publicado: (2023)

JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL
por: Wahnschaffe, Linus, et al.
Publicado: (2019)

Identification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis
por: Khan, Suleiman A., et al.
Publicado: (2014)

Novel Screening Method Identifies PI3Kα, mTOR, and IGF1R as Key Kinases Regulating Cardiomyocyte Survival
por: Elmadani, Manar, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mrv3kn81h6pi7cottup5nsjdju